Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Beta Bionics, Inc. (NASDAQ: BBNX)

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating potential misleading statements and omissions by Beta Bionics, Inc. that may have violated federal securities laws, following a significant drop in the company's stock price after disappointing financial results were announced [1][3]. Company Overview - Beta Bionics is a medical device company focused on designing, developing, and commercializing solutions for individuals with diabetes who require insulin [2]. Financial Performance - On January 8, 2026, Beta Bionics reported preliminary, unaudited topline financial results for Q4 2025, indicating at least 5,581 new patient starts, which fell short of the consensus expectation of 6,078 [3]. - Following the announcement, Beta Bionics' stock price decreased by approximately $11.85, or 37%, closing at $20.14 on January 9, 2026 [3].